Author: Li, Lili; Gao, Meiling; Li, Jie; Zu, Shulong; Wang, Yanan; Chen, Chunfeng; Wan, Dingyi; Duan, Jing; Aliyari, Roghiyh; Wang, Jingfeng; Zhang, Jicai; Jin, Yujie; Huang, Weijin; Jin, Xiaoxia; Shi, Minxin; Wang, Youchun; Qin, Chengâ€Feng; Yang, Heng; Cheng, Genhong
Title: Methods to Identify Immunogenic Peptides in SARSâ€CoVâ€2 Spike and Protective Monoclonal Antibodies in COVIDâ€19 Patients Cord-id: otskke98 Document date: 2021_6_19
ID: otskke98
Snippet: The severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) infection and the associated COVIDâ€19 diseases are an emerging threat to global public health. Although considerable scientific research on the immune, especially antibody, responses to SARSâ€CoVâ€2 infection have been conducted, additional dominant epitopes and protective antibodies are needed for diagnosis and treatment of COVIDâ€19 patients. Here, two different phage libraries are used to identify immunogenic epitopes a
Document: The severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) infection and the associated COVIDâ€19 diseases are an emerging threat to global public health. Although considerable scientific research on the immune, especially antibody, responses to SARSâ€CoVâ€2 infection have been conducted, additional dominant epitopes and protective antibodies are needed for diagnosis and treatment of COVIDâ€19 patients. Here, two different phage libraries are used to identify immunogenic epitopes across the spike protein and monoclonal antibodies from COVIDâ€19 patients. Three peptides are further characterized in the receptorâ€binding motif (RBM) and measured their antibody levels in COVIDâ€19 patients, from which one identifies one most immunodominant epitope with the highest antibody response in COVIDâ€19 patients and in immunized mice. More importantly, monoclonal antibodies specifically binding to this peptide isolated from COVIDâ€19 patients have therapeutic potential to neutralize SARSâ€CoVâ€2 infection. Thus, the approaches to systemically identify immunogenic peptides and directly identify human monoclonal antibodies from patients will provide useful diagnostic and therapeutic tools for COVIDâ€19 and other emerging infectious diseases.
Search related documents:
Co phrase search for related documents- accession number and acute respiratory syndrome coronavirus: 1, 2, 3
- accession number and luciferase reporter: 1
- accession number and lung tissue: 1
- acid peptide and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acid peptide and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acid peptide and low homology: 1
- acid testing and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acid testing and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acid testing and luciferase reporter: 1
- acute respiratory syndrome and low homology: 1, 2, 3, 4, 5
- acute respiratory syndrome and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute respiratory syndrome and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and low homology: 1, 2, 3
- acute respiratory syndrome coronavirus and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory syndrome coronavirus and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- low homology and luciferase reporter: 1
Co phrase search for related documents, hyperlinks ordered by date